抗血栓療法におけるファーマコゲノミクス検査の現状

• 中谷 中

  三重大学医学部附属病院中央検査部・オーダーメイド医療部

書誌事項

タイトル別名

• Pharmacogenomics in antithrombic therapy

抄録

Pharmacogenomics is the study of how genes affect a person's response to drugs. This relatively new field combines pharmacology (the science of drugs) and genomics (the study of genes and their functions) to develop effective, safe medications and doses that will be tailored to a person's genetic makeup. Warfarin is the most widely used oral anticoagulant in the world for patients with venous thrombosis, pulmonary embolism, chronic atrial fibrillation, and prosthetic heart valves. However, warfarin is difficult to use because of the wide interindividual variation in dose requirements, the narrow therapeutic range and the risk of serious bleeding. Genetic variants in the cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) were reported to correlate with warfarin sensitivity. Genotyping of CYP2C9 and VKORC1 is a quite useful predictor for warfarin effects and safety.<br>In this paper, I showed basic pharmacogenomics research and its clinical applications in antithrombic therapy.

収録刊行物

• 日本血栓止血学会誌

  日本血栓止血学会誌 23 (5), 443-449, 2012

  一般社団法人 日本血栓止血学会

キーワード

• pharmacogenomics
• warfarin
• personalized medicine

詳細情報

• CRID: 1390282679427332736
• NII論文ID: 130002076998
• DOI: 10.2491/jjsth.23.443
• ISSN: 18808808
• ISSN: 09157441
• 本文言語コード: ja
• データソース種別:
  • JaLC
  • Crossref
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可